Clinical Trial Update: Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating cetuximab in lung adenocarcinoma patients who developed acquired resistance to erlotinib; the study is completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-04-30